These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29935800)

  • 1. Developments in urologic oncology "OncoForum": The best of 2017.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp (Engl Ed); 2018 Oct; 42(8):488-498. PubMed ID: 29935800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in urologic oncology «OncoForum»: The best of 2016.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo JM
    Actas Urol Esp; 2017 Nov; 41(9):543-551. PubMed ID: 28734596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in urologic oncology «OncoForum»: The best of 2015.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp; 2016; 40(6):361-9. PubMed ID: 27061663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in urologic oncology "OncoForum": The best of 2019.
    Gómez-Veiga F; Alcaraz Asensio A; Burgos Revilla J; Cózar Olmo J
    Actas Urol Esp (Engl Ed); 2020 Nov; 44(9):586-596. PubMed ID: 32948345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in uro-oncology "OncoForum": the best of 2013.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp; 2014 Oct; 38(8):491-8. PubMed ID: 24731526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in urologic oncology 'OncoForum': The best of 2014.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp; 2015 Jun; 39(5):271-8. PubMed ID: 25770399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in uro-oncology «Oncoforum»: the best of 2011].
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp; 2012 Oct; 36(9):507-14. PubMed ID: 22520042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla JM; Cózar-Olmo FJ
    Actas Urol Esp (Engl Ed); 2022 May; 46(4):214-222. PubMed ID: 34844900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What's new in 2009 in prostate cancer: highlights from ASTRO, EAU, ASCO and AUA meetings].
    Salomon L; Peyromaure M; Mongiat-Artus P; Roset F; Gachignard N; Bastide C; Richaud P; Beuzeboc P; Cornud F; Molinié V; Soulié M; Benchikh El Fegoun A;
    Prog Urol; 2010 Mar; 20 Suppl 1():S61-7. PubMed ID: 20493449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.